(Q60710884)

English

Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning

No description defined

In more languages

Statements

scholarly article

0 references

Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning (English)

0 references

1 reference

based on heuristic

inferred from title

Eshetu G. Atenafu

object named as

E G Atenafu

3

0 references

author name string

M Shanavas

1

0 references

H A Messner

2

0 references

E G Atenafu

3

0 references

D H Kim

4

0 references

J Kuruvilla

5

0 references

J H Lipton

6

0 references

J Uhm

7

0 references

M Seftel

8

0 references

N Alam

9

0 references

V Gupta

10

0 references

language of work or name

0 references

publication date

September 2014

0 references

30 June 2014

0 references

Bone Marrow Transplantation

0 references

49

0 references

9

0 references

1162-9

0 references

1162-1169

0 references

https://scigraph.springernature.com/pub.10.1038/bmt.2014.131

0 references

Fludarabine, busulfan, antithymocyte globulin, and total body irradiation for pretransplantation conditioning in acute lymphoblastic leukemia: excellent outcomes in all but older patients with comorbidities

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Importance of day 21 BM chimerism in sustained neutrophil engraftment following double-unit cord blood transplantation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence and Risk Factors for Early Hepatotoxicity and Its Impact on Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Allogeneic stem cell transplantation for myelofibrosis in 2012.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1994 Consensus Conference on Acute GVHD Grading

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis resear

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Venoocclusive disease of the liver following bone marrow transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcome of transplantation for myelofibrosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regimen-related toxicity in patients undergoing bone marrow transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Stem cell transplantation for myelofibrosis: a report from two Canadian centers

1 reference

https://pubmed.ncbi.nlm.nih.gov/24978138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Scouting out the neighborhood in AIDS-related lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.131

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/BMT.2014.131

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q60710884&oldid=1934424841"